Is Pegasys Approved for Hepatitis B in Children?
Pegasys (peginterferon alfa-2a) is FDA-approved for treating chronic hepatitis B in children aged 5 years and older who weigh at least 20 kg. It is used as monotherapy for HBeAg-positive or HBeAg-negative cases, with dosing based on body surface area (180 mcg/1.73 m² weekly via subcutaneous injection for 48 weeks).[1][2]
What Does Clinical Data Show for Kids?
In pediatric trials, HBeAg-positive children (ages 5-17) achieved HBeAg seroconversion in 23-30% of cases after 48 weeks of Pegasys, compared to 19-21% with standard interferon alfa-2a. HBsAg clearance occurred in about 3% at 48 weeks and 7% after 72 weeks of follow-up. Safety profiles mirrored adults, with common side effects like flu-like symptoms, neutropenia, and growth issues, though most resolved post-treatment.[1][3]
How Does It Compare to Adult Use or Other Options?
Pegasys dosing and duration (48 weeks) align with adult hepatitis B regimens, but pediatric approval excludes those under 5 years or lighter than 20 kg due to limited data. Alternatives like entecavir or tenofovir are oral nucleos(t)ide analogs approved for kids as young as 2, often preferred for better tolerability and compliance, though they suppress rather than clear the virus.[1][4]
What Are Common Side Effects in Children?
Children on Pegasys report similar adverse events to adults: injection-site reactions (62%), fever (50%), fatigue (41%), neutropenia (39%), headache (36%), and alopecia (28%). Growth velocity often normalizes after stopping therapy, but monitoring is required. It's contraindicated in decompensated liver disease or autoimmune disorders.[1][2]
When Is It Not Recommended for Kids?
Avoid in children under 5 years, those with psychiatric issues (e.g., severe depression), uncontrolled thyroid disease, or pregnancy. Use requires weighing benefits against risks like retinopathy or thyroid dysfunction, with regular blood tests mandated.[1][3]
[1]: FDA Label for Pegasys
[2]: Drugs.com - Pegasys Prescribing Information
[3]: Hepatitis B Foundation - Pediatric Treatment Guidelines
[4]: AASLD Hepatitis B Guidance